biostrategy’s Activity

Wed Dec 4

NL

Article

biostrategy published an article 6:24 AM

Orexigen Therapeutics: Light at the End of the Tunnel?

Orexigen Therapeutics announces successful interim results for its lead product candidate Contrave followed by the potentially share dilutive announcement of $100 million convertible senior notes offering. Which way should the stock go?

Tue Nov 12

NL

Article

biostrategy published an article 4:29 AM

Looking at the Future of Salix Pharmaceuticals

Let's dive deeper at Salix Pharmaceuticals' acquisition of Santarus and its lead drug Uceris.

Wed Nov 6

NL

Article

biostrategy published an article 4:54 AM

Seattle Genetics Is Down but Not Out

Seattle Genetics share price has been trending lower lately due to adverse side effects experienced by some patients undergoing clinical trials with the company’s lead product Adcetris. Since long term prospects look bright forSeattle, this could be [more]

Mon Nov 4

NL

Article

biostrategy published an article 9:15 AM

Celgene's Product Portfolio Performance Boosts Valuation Prospects

Celgene, which has almost doubled in value since the begining of the year, reported a strong 3rd quarter performance, raised its EPS guidance for the year and is poised for another exceptional year in 2014.

Thu Oct 24

NL

Article

biostrategy published an article 2:03 PM

Regeneron's Eylea Is on Its Way Toward Blockbuster Status

Regeneron's Eylea U.S. sales are expected to reach $1.3 billion in 2013, qualifying it for a blockbuster status after just two full years on the market.

CAPS Stats & Trivia

CAPS Player Rating < 20
Player Rank 0 out of 74977
Score 0.00
Score Change Today -5.41
Accuracy 0.00%
Active Picks 5
Total Picks 10
Best Pick HSP (+27.48)
Worst Pick FRX (-16.01)
Average Score per Pick -1.78
Charms Earned 0
Highest Rated Favorite No Favorites Selected
Go to biostrategy’s CAPS page

Boards Stats & Trivia

Board Posts 0
Recs Received 0
People who have rec'd these posts 0
Recs to Posts Ratio (last 30 days) N/A
Threads Started 0
Threads Started Percentage 0.00 %
Most Frequent Board N/A
Very First Post N/A
Percentage of Posts Rec'd 100.00 %
Show biostrategy’s 10 Latest Posts